Audit: QRS - Betaine for Health & Longevity
Audit conducted on 20/07/2026 04:16 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 83 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol doses, biomarker targets, benefit/risk items, and cadence trace to the ER (Protocol, Monitoring, Benefits, Risks sections). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Speculative tiers and “if they occur”/”where present” hedges mirror the ER. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening/softening detected. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications and interactions both drawn from the ER Key Interactions & Contraindications section without cross-relabeling. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, NCTs, expert names, or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Objective, data-driven register consistent with the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Met. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence, not directives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Footer disclaimer present; body avoids prescriptive advice. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content is presented, not recommended. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact cards and lists. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No “you” phrasing. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing matches this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Monitoring/protocol detail consistent with this audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not written for the general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Benefit/risk weighting reflects the target audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | Uses “longevity”; no “anti-aging”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Formal terminology; “stomach upset” is pulled verbatim from the ER qualitative-marker list. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”). | 🟢 | All fixed labels present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All expected variable spans present and populated. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | No unexpected span modifications. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. | N/A | No source ER section is empty; every populated section had content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol/monitoring labels match ER wording. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels preserved. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emojis; ER “⚠️ Conflicted” markers correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section with more ER content than the per-section budget is condensed, not extended onto a second page. | 🟢 | Content condensed to fit one page. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is the first element (lines 2–14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but not parsed as YAML. | 🟢 | YAML delimited by — at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless the value requires YAML quoting. | 🟢 | Only duration is quoted (contains a colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]”. | 🟢 | er_filename: betaine_2026-0720-0143_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”. | 🟢 | qrs_prompt_version: 26.7.02. |
| 5.7 | Creation date and time is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”. | 🟢 | qrs_creation_date: 2026-0720-0409. |
| 5.8 | The nickname of the AI is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”. | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus”. |
| 5.10 | The full name of the AI is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”. | 🟢 | qrs_creator_ai_fullname: Opus 4.8. |
| 5.11 | The full name consists of the nickname and the model version number and no additional qualifier. | 🟢 | “Opus 4.8”. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]”. | 🟢 | qrs_filename: betaine_2026-0720-0143_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required. | 🟢 | Values clean and consistent. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Betaine for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Betaine for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]. | 🟢 | 2026-0720 → 07/20/2026. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname]. | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only title and subline; no extras. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section. |
🟢 | Distills the two-function framing, homocysteine benefit, mixed strength/body-composition signal, and cholesterol trade-off from the Conclusion. |
| 7.2 | [at_a_glance] is no longer than 60 words. | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a Conclusion passage (lines 432–434). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge; uses plain-language terms instead. | 🟢 | Uses “methyl tags”, “blood marker”, “cholesterol”; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values). | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results. | 🟢 | No statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Sourced from the ER “Populations who should avoid or use caution” bullet (line 293). |
| 8.2 | [stop_items] represent the Contraindications from the ER. | 🟢 | Pregnancy/breastfeeding, high LDL/FH/ASCVD, kidney impairment, trimethylaminuria all captured. |
| 8.3 | Individual [stop_items] are formatted as <li></li>. | 🟢 | Four <li> items. |
| 8.4 | Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. | 🟢 | No trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | “>160 mg/dL” threshold and “(high doses)” qualifier preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase, normalize items to a plain comma-separated list. | 🟢 | No ambiguous ranking notation; “>160 mg/dL” is a threshold, retained correctly. |
| 8.7 | If no [stop_items] are present the section is left empty. | N/A | Stop items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Drawn from the ER interaction bullets (lines 281–291). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications. | 🟢 | Six interactions carried; none overlap the contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li>. | 🟢 | Six <li> items. |
| 9.4 | Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. | 🟢 | Labels only; severity/consequence text dropped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | Example-drug lists preserved (folate/B6/B12; NR/NMN; methotrexate/trimethoprim/sulfasalazine; statins/ezetimibe). |
| 9.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize to a plain comma-separated list. | 🟢 | No ranking notation present; example lists rendered as plain comma-separated lists. |
| 9.7 | If no [caution_items] are present the section is left empty. | N/A | Caution items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section. |
🟢 | Dose/frequency/timing sourced from the ER Therapeutic Protocol (lines 315–327). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section. |
🟢 | Dose, Frequency, Timing. |
| 10.3 | If less than three distinct actionable aspects are mentioned, the unused sets are left empty and invisible. | N/A | Three distinct aspects are present. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three sets populated with ER-derived content. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER. | 🟢 | Homocysteine, Performance/body composition, Liver effects (ER line 366). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit. | 🟢 | High → Medium → Low benefit ordering. |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned, the unused sets are left empty and invisible. | N/A | Three distinct aspects are present. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All three sets populated. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel. |
N/A | The ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section. |
🟢 | Tiers mirror the ER Expected Benefits headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]. | 🟢 | All four populated. |
| 12.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. | 🟢 | Bare benefit names only. |
| 12.4 | Parenthetical content — effect sizes, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried; “⚠️ Conflicted” markers removed. |
| 12.5 | If no items of a specific sub-section are present the respective span is set to display=none, not filled with empty-state phrasing. | N/A | All four benefit tiers contain items. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section. |
🟢 | Tiers mirror the ER Risks headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]. | 🟢 | All four populated. |
| 13.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. | 🟢 | Bare risk names only. |
| 13.4 | Parenthetical content — frequencies, severity grades, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | “(Fishy, Trimethylamine)” and “(TMAO)” parentheticals stripped. |
| 13.5 | If no items of a specific sub-section are present the respective span is set to display=none, not filled with empty-state phrasing. | N/A | All four risk tiers contain items. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section. |
🟢 | Sourced from ER Monitoring Protocol biomarker table (lines 398–405). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed. |
🟢 | All six biomarkers (homocysteine, LDL, total cholesterol, B12 & folate, methionine, ALT) present. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. |
🟢 | Cadence matches ER line 392. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section. |
🟢 | Sourced from the ER qualitative markers (lines 409–412). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed. |
🟢 | All four qualitative markers present. |
Issues 20/07/2026 04:16
Pass rate 100.00%. No issues found.